CA3116552A1 - Methods for the treatment of solid tumor cancers using illudins and biomarkers - Google Patents

Methods for the treatment of solid tumor cancers using illudins and biomarkers Download PDF

Info

Publication number
CA3116552A1
CA3116552A1 CA3116552A CA3116552A CA3116552A1 CA 3116552 A1 CA3116552 A1 CA 3116552A1 CA 3116552 A CA3116552 A CA 3116552A CA 3116552 A CA3116552 A CA 3116552A CA 3116552 A1 CA3116552 A1 CA 3116552A1
Authority
CA
Canada
Prior art keywords
cancer
biological sample
expression
illudin
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3116552A
Other languages
English (en)
French (fr)
Inventor
Aditya KULKAMI
Yuvanesh VEDARAJU
Umesh KATHAD
Arun ASAITHAMBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of CA3116552A1 publication Critical patent/CA3116552A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3116552A 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers Pending CA3116552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745382P 2018-10-14 2018-10-14
US62/745,382 2018-10-14
PCT/US2019/056039 WO2020081414A1 (en) 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers

Publications (1)

Publication Number Publication Date
CA3116552A1 true CA3116552A1 (en) 2020-04-23

Family

ID=70284107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3116552A Pending CA3116552A1 (en) 2018-10-14 2019-10-14 Methods for the treatment of solid tumor cancers using illudins and biomarkers

Country Status (6)

Country Link
EP (1) EP3863615A4 (de)
JP (2) JP2022513349A (de)
CN (1) CN113194934B (de)
AU (2) AU2019361781A1 (de)
CA (1) CA3116552A1 (de)
WO (1) WO2020081414A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146181A4 (de) * 2020-05-08 2024-10-09 Lantern Pharma Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
JP2023551709A (ja) * 2020-11-18 2023-12-12 ランタン ファルマ インコーポレイテッド がん薬物感受性決定マーカー
CN116847834A (zh) * 2021-01-08 2023-10-03 蓝腾制药公司 使用隐陡头菌素或羟基脲甲基酰基富烯治疗脑转移瘤和cns转移瘤
JP2024528725A (ja) * 2021-07-29 2024-07-30 ランタン ファルマ インコーポレイテッド Ｐａｒｐ阻害剤及びアシルフルベンの併用によるがんの治療
KR20240073856A (ko) * 2021-07-29 2024-05-27 랜턴 파마 인코포레이티드 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
EP4554683A2 (de) * 2022-07-15 2025-05-21 Lantern Pharma Inc. Verfahren zur behandlung von brustkrebs und parp-resistentem brustkrebs
CN116287275B (zh) * 2023-04-10 2024-04-05 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Ptgr1作为cdk4/6抑制剂与二甲双胍联合用药指导标志物的应用
CN117233391A (zh) * 2023-08-28 2023-12-15 南方医科大学南方医院 一种用于预测胃癌免疫治疗和/或化疗疗效的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039210B2 (en) * 2004-05-14 2011-10-18 The Johns Hopkins University Protein tyrosine phosphatase mutations in cancers
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
JP5429735B2 (ja) * 2009-03-25 2014-02-26 富士フイルム株式会社 食道癌の検出方法及び抑制剤
AU2013202104B2 (en) * 2012-01-13 2015-11-26 Celgene Corporation Biomarkers for the treatment of hepatocellular carcinoma
US10285955B2 (en) * 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
WO2015157578A2 (en) * 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
EP3161489A4 (de) * 2014-06-26 2018-04-18 Institute for Systems Biology Marker und therapeutische indikatoren für glioblastoma multiforme (gbm)
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US20210137850A1 (en) * 2017-03-15 2021-05-13 Memorial Sloan Kettering Cancer Center Diagnosis & treatment of ercc3-mutant cancer

Also Published As

Publication number Publication date
EP3863615A4 (de) 2022-08-03
CN113194934B (zh) 2025-02-25
WO2020081414A1 (en) 2020-04-23
AU2019361781A1 (en) 2021-06-03
JP2025111438A (ja) 2025-07-30
JP2022513349A (ja) 2022-02-07
EP3863615A1 (de) 2021-08-18
CN113194934A (zh) 2021-07-30
AU2025234250A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
CN113194934B (zh) 使用隐陡头菌素和生物标志物治疗实体肿瘤癌症的方法
Li et al. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
US20210230662A1 (en) Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers
Carney et al. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer
EP2560006A2 (de) Biomarker von Prostatakrebs und Verfahren zu deren Verwendung
US20200249235A1 (en) Methods for diagnosing pancreatic cancer
JP2012526544A5 (de)
US20160274114A1 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
KR20190106809A (ko) 종양 조직을 프로파일링하기 위한 srm/mrm 검정
US20110091487A1 (en) Melanoma biomarker and methods of uses
JP2013027387A (ja) 膵臓癌バイオマーカー
JP2017503503A (ja) Ｐｄ−ｌ１に対するｓｒｍアッセイ
US20160169901A1 (en) Methods for diagnosis of cutaneous t-cell lymphoma
JP2012526543A5 (de)
WO2020197505A1 (en) Biomarker with therapeutic implications for peritoneal carcinomatosis
JP5736947B2 (ja) 新規胆道癌バイオマーカー
US20220299514A1 (en) Biomarkers of therapeutic responsiveness
US11988672B2 (en) CCL24 as a diagnostic and therapeutic target for breast cancer
Kim et al. Small heterodimer partner as a predictor of neoadjuvant radiochemotherapy response and survival in patients with rectal cancer: A preliminary study
KR20220063630A (ko) 췌장암 진단 또는 예후 예측용 조성물 및 이의 용도
KR102787762B1 (ko) 독성 간염의 진단 또는 예후 예측 마커 및 이를 이용한 독성 간염 진단 또는 예후 예측 방법
US20250290155A1 (en) Clinical workflow for treatment of breast cancer
WO2024258937A1 (en) Biomarkers and methods of treatment of follicular lymphoma
Jiang et al. Bone marrow-based highly sensitive proteomics profiling reveals valuable biomarkers for pediatric B-cell acute lymphoblastic leukemia
JP2025102738A (ja) 血中循環腫瘍細胞を単離及び分析する方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240807

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240807

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240807

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241015

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241015

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250723

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250723

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251121

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260323

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260324

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260324